Divi’s Laboratories - Custom Synthesis Drives Earnings; Generics Stable QoQ
Divi’s Laboratories (DIVI) delivered in-line revenue. However, it reported better-than-expected EBITDA/PAT led by a better product mix and lower...
196 Views
Divis Laboratories Ltd - Company Set for Continued Growth
Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates.
208 Views
Parallel Trades - Strategy - We Suggest Going
To ensure rupee neutral strategy, we suggest going long on DIVISLAB with 1 lot(s) and going short on AARTIIND with 1 lot(s)
410 Views
Divi’s Laboratories - Miss in 2QFY23; Growth Factors to Face Softness over Medium Term
DIVI delivered an earnings miss in 2QFY23. Reduced traction in Custom Synthesis (CS), coupled with lower operating leverage resulted in an earnings...
445 Views
Custom Synthesis/Nutraceuticals drive earnings growth
DIVI delivered in line 2QFY22 earnings led by strong offtake in the Custom Synthesis (CS) segment and ramp up in the Nutraceuticals segment. It has...
163 Views